CA2776021C - Sulfonamides for the prevention of diabetes - Google Patents
Sulfonamides for the prevention of diabetes Download PDFInfo
- Publication number
- CA2776021C CA2776021C CA2776021A CA2776021A CA2776021C CA 2776021 C CA2776021 C CA 2776021C CA 2776021 A CA2776021 A CA 2776021A CA 2776021 A CA2776021 A CA 2776021A CA 2776021 C CA2776021 C CA 2776021C
- Authority
- CA
- Canada
- Prior art keywords
- diabetes
- days
- day
- meraxin
- reparixin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172365.0 | 2009-10-06 | ||
| EP09172365A EP2308485A1 (en) | 2009-10-06 | 2009-10-06 | Sulfonamides for the prevention of diabetes |
| PCT/EP2010/064920 WO2011042465A1 (en) | 2009-10-06 | 2010-10-06 | Sulfonamides for the prevention of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2776021A1 CA2776021A1 (en) | 2011-04-14 |
| CA2776021C true CA2776021C (en) | 2017-08-01 |
Family
ID=41716341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2776021A Active CA2776021C (en) | 2009-10-06 | 2010-10-06 | Sulfonamides for the prevention of diabetes |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8846755B2 (https=) |
| EP (2) | EP2308485A1 (https=) |
| JP (1) | JP5745526B2 (https=) |
| KR (1) | KR101737656B1 (https=) |
| CN (1) | CN102639128B (https=) |
| AU (1) | AU2010305384B2 (https=) |
| BR (1) | BR112012007989B1 (https=) |
| CA (1) | CA2776021C (https=) |
| CY (1) | CY1117599T1 (https=) |
| DK (1) | DK2485724T3 (https=) |
| EA (1) | EA021788B1 (https=) |
| ES (1) | ES2570463T3 (https=) |
| HR (1) | HRP20160399T1 (https=) |
| HU (1) | HUE028132T2 (https=) |
| IL (1) | IL219038A (https=) |
| ME (1) | ME02385B (https=) |
| MX (1) | MX2012004087A (https=) |
| NZ (1) | NZ599171A (https=) |
| PL (1) | PL2485724T3 (https=) |
| RS (1) | RS54693B1 (https=) |
| SI (1) | SI2485724T1 (https=) |
| SM (1) | SMT201600126B (https=) |
| WO (1) | WO2011042465A1 (https=) |
| ZA (1) | ZA201202462B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9844528B2 (en) * | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| EP2308485A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamides for the prevention of diabetes |
| EP3281937A1 (en) * | 2016-08-09 | 2018-02-14 | Dompé farmaceutici S.p.A. | Sulfonamides as gpr40- and gpr120-agonists |
| US11291641B2 (en) | 2016-10-03 | 2022-04-05 | The Children's Medical Center Corporation | Prevention and treatment of diabetic nephropathy |
| EP4686469A1 (en) | 2024-07-31 | 2026-02-04 | Dompé farmaceutici SpA | Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| ITMI20010206A1 (it) * | 2001-02-02 | 2002-08-02 | Dompe Spa | Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz |
| US20040242498A1 (en) * | 2003-02-27 | 2004-12-02 | Collins Tassie L. | CXCR3 antagonists |
| ATE444286T1 (de) | 2004-03-23 | 2009-10-15 | Dompe Pha R Ma Spa Res & Mfg | 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung |
| PT1579859E (pt) | 2004-03-25 | 2007-03-30 | Dompe Pha R Ma Spa Res & Mfg | Utilização de n-(2-aril-propionil)-sulfonamidas pata o tratamento de lesões da medula espinal |
| CN102088993A (zh) * | 2008-03-20 | 2011-06-08 | 卡罗勒斯治疗公司 | 炎症的治疗方法 |
| EP2308484A1 (en) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| EP2308485A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamides for the prevention of diabetes |
-
2009
- 2009-10-06 EP EP09172365A patent/EP2308485A1/en not_active Withdrawn
-
2010
- 2010-10-06 CA CA2776021A patent/CA2776021C/en active Active
- 2010-10-06 PL PL10768898T patent/PL2485724T3/pl unknown
- 2010-10-06 ES ES10768898T patent/ES2570463T3/es active Active
- 2010-10-06 US US13/500,522 patent/US8846755B2/en active Active
- 2010-10-06 MX MX2012004087A patent/MX2012004087A/es active IP Right Grant
- 2010-10-06 ME MEP-2016-71A patent/ME02385B/me unknown
- 2010-10-06 RS RS20160230A patent/RS54693B1/sr unknown
- 2010-10-06 AU AU2010305384A patent/AU2010305384B2/en active Active
- 2010-10-06 HU HUE10768898A patent/HUE028132T2/en unknown
- 2010-10-06 JP JP2012532578A patent/JP5745526B2/ja active Active
- 2010-10-06 EA EA201270512A patent/EA021788B1/ru unknown
- 2010-10-06 CN CN201080044851.6A patent/CN102639128B/zh active Active
- 2010-10-06 BR BR112012007989A patent/BR112012007989B1/pt active IP Right Grant
- 2010-10-06 EP EP10768898.8A patent/EP2485724B1/en active Active
- 2010-10-06 SI SI201031165T patent/SI2485724T1/sl unknown
- 2010-10-06 KR KR1020127010733A patent/KR101737656B1/ko active Active
- 2010-10-06 HR HRP20160399TT patent/HRP20160399T1/hr unknown
- 2010-10-06 WO PCT/EP2010/064920 patent/WO2011042465A1/en not_active Ceased
- 2010-10-06 NZ NZ599171A patent/NZ599171A/en unknown
- 2010-10-06 DK DK10768898.8T patent/DK2485724T3/en active
-
2012
- 2012-04-04 ZA ZA2012/02462A patent/ZA201202462B/en unknown
- 2012-04-04 IL IL219038A patent/IL219038A/en active IP Right Grant
-
2014
- 2014-09-26 US US14/497,637 patent/US9556115B2/en active Active
-
2016
- 2016-05-03 SM SM201600126T patent/SMT201600126B/it unknown
- 2016-05-06 CY CY20161100375T patent/CY1117599T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wilding | The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors | |
| EP2579879B1 (en) | Triazine derivatives for delaying the onset of type 1 diabetes | |
| US9556115B2 (en) | Sulfonamides for the prevention of diabetes | |
| Marques et al. | Treatment of calcium channel blocker intoxication with insulin infusion: case report and literature review | |
| KR20150046125A (ko) | Sglt2 저해약과 항고혈압약의 조합 | |
| US20250281478A1 (en) | Methods for preventing or treating kidney diseases | |
| US20240245641A1 (en) | Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin | |
| Azendour et al. | Severe amlodipine intoxication treated by hyperinsulinemia euglycemia therapy | |
| CN104582701A (zh) | 减轻体重的方法 | |
| EP2854807A1 (en) | A method of improving liver function | |
| HK1174557B (en) | Sulfonamides for the prevention of diabetes | |
| CN114984005B (zh) | 硫酸舒欣啶在制备抗肾功能衰竭药物中的应用 | |
| Ke et al. | Efficacy and safety of a combination of miglitol, metformin and insulin aspart in the treatment of type 2 diabetes | |
| US20210100872A1 (en) | Pharmacological Formulation Comprising Cyclo (HIS-PRO) As Effective Ingredient For Preventing Or Treating Diabetes Mellitus | |
| Poglajen et al. | Prolonged Release Tacrolimus Has Comparable Safety and Efficacy Profile as Standard Release Tacrolimus in Heart Transplant Recipients | |
| AU2016206292B2 (en) | A method of improving liver function | |
| Czapska et al. | Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus | |
| Ripal et al. | A Review of Nateglinide in the Management of Type 2 Diabetes | |
| JP2008525314A (ja) | 胃不全麻痺様症状の治療及び／又は予防剤 | |
| EGGLESTON et al. | Transcription of Pamel Meeting on Therapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20151001 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250926 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250926 |